Supergenerics and Value-Added Medicines Explained: Complete Guide to Regulatory Pathways, Strategies, and Compliance 2025 Supergenerics and Value-Added Medicines: Global Regulatory Guide for Differentiated Pharma Products Introduction to Supergenerics and Value-Added Medicines Supergenerics (also known as value-added medicines) are enhanced versions of existing generics, offering improvements such as new formulations, delivery systems, indications, or combinations. Unlike standard generics that only demonstrate bioequivalence, supergenerics involve modifications that add therapeutic or commercial value. Regulatory authorities including the FDA, EMA, and CDSCO have defined pathways such as FDA’s 505(b)(2) NDA or EMA’s Article 10(3) hybrid application for these products. By 2025, supergenerics are a…